Received Sep 29, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | UNK | — |
Pain, swelling, redness at site; Pain, swelling, redness at site; Pain, swelling, redness at site; Muscle ache; This non-serious case was reported by a consumer and described the occurrence of injection site pain in a 54-year-old female patient who received Herpes zoster (Shingles vaccine) for prophylaxis. Concurrent medical conditions included multiple sclerosis. Concomitant products included ofatumumab (Kesimpta). On 27-AUG-2025, the patient received Shingles vaccine. On 27-AUG-2025, less than a day after receiving Shingles vaccine, the patient experienced injection site pain (Verbatim: Pain, swelling, redness at site), injection site swelling (Verbatim: Pain, swelling, redness at site), injection site erythema (Verbatim: Pain, swelling, redness at site) and muscle pain (Verbatim: Muscle ache). The outcome of the injection site pain, injection site swelling, injection site erythema and muscle pain were not resolved. It was unknown if the reporter considered the injection site pain, injection site swelling, injection site erythema and muscle pain to be related to Shingles vaccine. It was unknown if the company considered the injection site pain, injection site swelling, injection site erythema and muscle pain to be related to Shingles vaccine. Additional Information: GSK Receipt Date: 30-AUG-2025 The patient self-reported this case for herself. The patient stated that she had multiple sclerosis (MS), and her neurologist had recommended administration of the shingles vaccine. Following vaccination, the patient experienced pain, swelling, and redness at the injection site, as well as muscle aches. No treatment was administered for these symptoms.
Multiple sclerosis
KESIMPTA